LIS-1 is under clinical development by Xenothera and currently in Phase II for Kidney Transplant Rejection. According to GlobalData, Phase II drugs for Kidney Transplant Rejection have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LIS-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LIS-1 overview

LIS-1 (polyclonal antibodies) are under development for kidney transplantation, graft versus host disease and graft rejection following solid organ transplantation. The drug candidates are polyclonal antibodies developed based on Xenothera technology platform involving generation of hyperimmune polyclonal sera. It is administered through intravenous route.

Xenothera overview

Xenothera, is a xenotherapy platform with embedded technology that renovates immunological treatments. The company is headquartered in France.

For a complete picture of LIS-1’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.